来自Cyclocarya paliurus的Cypaliuruside F对HepG2细胞的抗瘤作用
Shan-Bin Li1, Jian Zou1, Tong-Shi-Yao Zhao1
1Education Department of Guangxi Zhuang Autonomous Region, Key Laboratory of Biochemistry and Molecular Biology (Guilin Medical University), Guilin, P. R. China.
Natural product research
|May 21, 2024
概括
环氨酸F是一种来自Cyclocarya paliurus的化合物,通过诱导细胞亡和细胞循环停止来抑制肝癌 (HepG2) 细胞生长. 这种天然化合物显示出作为抗瘤剂的潜力.
科学领域:
- 植物化学 植物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肝细胞癌 (HCC) 仍然是一个重大的全球健康挑战.
- 自然产品为新型癌症治疗提供了一个有希望的途径.
- 赛克洛卡利亚帕利乌鲁斯 (Cyclocarya paliurus) 是一种具有传统药用用途的植物.
研究的目的:
- 从Cyclocarya paliurus中分离和表征一种新型的马兰三烯酸盐,Cypaliuruside F,从Cyclocarya paliurus中.
- 为了研究Cypaliuruside F对HepG2细胞的体外抗瘤作用.
- 阐明其抗HCC活性背后的分子机制.
主要方法:
- 孤立和结构阐明的Cypaliuruside F. 的.
- 在体外测试:MTT,流细胞计,细胞划痕,DAPI对HepG2细胞进行染色.
- 网络药理学,分子对接和西方斑点分析.
主要成果:
- 赛帕鲁胺F显著抑制了HepG2细胞的增殖.
- 该化合物诱导HepG2细胞的亡和细胞循环停止.
- 分子分析表明抑制mTOR,STAT3和Bcl-2,并激活Bax.
结论:
- 赛帕化F对肝细胞癌细胞表现出强大的抗瘤活性.
- 该机制涉及诱导亡和细胞循环停止.
- 这种达马兰三基酸盐素是HCC治疗的潜在候选者.
更多相关视频
10:38Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs
Published on: December 16, 2022
2.1K
09:03Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
348
相关概念视频
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K